Tema Etfs LLC Has $3.62 Million Stock Position in Amgen Inc. $AMGN

Tema Etfs LLC lifted its stake in Amgen Inc. (NASDAQ:AMGN) by 33.3% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 12,977 shares of the medical research company’s stock after buying an additional 3,243 shares during the period. Tema Etfs LLC’s holdings in Amgen were worth $3,623,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. Laurel Wealth Advisors LLC grew its position in Amgen by 27,765.8% in the second quarter. Laurel Wealth Advisors LLC now owns 6,700,621 shares of the medical research company’s stock valued at $1,870,880,000 after acquiring an additional 6,676,575 shares during the period. Norges Bank bought a new position in shares of Amgen during the second quarter valued at $1,663,726,000. Nuveen LLC acquired a new stake in shares of Amgen in the 1st quarter valued at $688,868,000. Vanguard Group Inc. boosted its stake in shares of Amgen by 1.6% in the 2nd quarter. Vanguard Group Inc. now owns 53,711,570 shares of the medical research company’s stock valued at $14,996,807,000 after purchasing an additional 841,117 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. grew its holdings in shares of Amgen by 5.6% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 12,893,677 shares of the medical research company’s stock worth $3,600,043,000 after purchasing an additional 687,735 shares during the last quarter. Institutional investors own 76.50% of the company’s stock.

Insider Activity at Amgen

In related news, SVP Rachna Khosla sold 890 shares of Amgen stock in a transaction dated Wednesday, November 12th. The stock was sold at an average price of $336.24, for a total value of $299,253.60. Following the completion of the sale, the senior vice president directly owned 7,082 shares in the company, valued at $2,381,251.68. This trade represents a 11.16% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Murdo Gordon sold 6,879 shares of the business’s stock in a transaction dated Wednesday, November 12th. The stock was sold at an average price of $336.83, for a total value of $2,317,053.57. Following the sale, the executive vice president directly owned 41,923 shares of the company’s stock, valued at $14,120,924.09. This represents a 14.10% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 10,908 shares of company stock worth $3,674,966 over the last 90 days. Insiders own 0.76% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on AMGN shares. Citigroup lifted their price target on shares of Amgen from $310.00 to $315.00 and gave the company a “neutral” rating in a report on Wednesday, September 24th. Daiwa Capital Markets raised their price objective on shares of Amgen from $310.00 to $370.00 and gave the stock an “outperform” rating in a report on Tuesday, November 18th. Truist Financial started coverage on shares of Amgen in a research note on Monday, November 24th. They issued a “hold” rating and a $318.00 target price for the company. Deutsche Bank Aktiengesellschaft increased their price target on Amgen from $280.00 to $285.00 and gave the stock a “hold” rating in a research report on Tuesday, November 11th. Finally, Piper Sandler raised their price target on Amgen from $342.00 to $381.00 and gave the company an “overweight” rating in a report on Friday, November 14th. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $335.65.

Amgen Trading Down 1.5%

Shares of NASDAQ AMGN opened at $340.16 on Friday. Amgen Inc. has a 1-year low of $253.30 and a 1-year high of $346.38. The company has a 50-day moving average of $312.27 and a two-hundred day moving average of $296.72. The company has a market cap of $183.17 billion, a PE ratio of 26.29, a P/E/G ratio of 3.12 and a beta of 0.45. The company has a current ratio of 1.28, a quick ratio of 0.99 and a debt-to-equity ratio of 5.45.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Tuesday, November 4th. The medical research company reported $5.64 earnings per share for the quarter, beating analysts’ consensus estimates of $5.01 by $0.63. Amgen had a net margin of 19.47% and a return on equity of 162.59%. The business had revenue of $9.56 billion during the quarter, compared to analyst estimates of $8.98 billion. During the same quarter last year, the business posted $5.58 earnings per share. Amgen’s revenue for the quarter was up 12.4% compared to the same quarter last year. Amgen has set its FY 2025 guidance at 20.600-21.400 EPS. As a group, equities analysts expect that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, December 12th. Stockholders of record on Friday, November 21st will be paid a dividend of $2.38 per share. This represents a $9.52 annualized dividend and a dividend yield of 2.8%. The ex-dividend date of this dividend is Friday, November 21st. Amgen’s dividend payout ratio is 73.57%.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.